Experienced Pharmaceutical Executive and Research Manager who has spent >18 years leading Drug Discovery groups in both big Pharma and Biotech, including having responsibility for all aspects of Drug Discovery. Involved in progressing several compounds from Discovery into Development, some of which have now reached market. Prior to establishing McC+R&D Consulting with Dr. Christine Reynet in 2009 as an independent pharmaceutical consultancy business, was Senior Vice President of Research and Chief Scientific Officer at (OSI) Prosidion in Oxford, UK. Joined (OSI) Prosidion as VP Research & CSO in 2004, and was with OSI since June 2002 when appointed VP of UK Discovery for (OSI) Pharmaceuticals in Oxford. Prior to this was VP for Scientific Affairs at Novo Nordisk, Denmark, where was previously Director then VP of Target Cell Biology (1998-2001) and Director of Diabetes Discovery (1996-1998). Prior to Novo, was Principal Scientist and Head of Biochemical Pharmacology at Syntex Research (later Roche) in Edinburgh (1990-1995), a tenured lecturer in Biochemistry at Leeds University (1985-1990) and a Research Fellow of the Lister Institute of Preventive Medicine (1988-1990). Degrees are in Biochemistry from Glasgow (B.Sc., 1976) and Bristol (Ph.D., 1980; D.Sc., 1991) Universities. Have authored or co-authored over 120 full papers within the fields of metabolic regulation and signaling, and in drug discovery.